Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2

Research output: Contribution to journalJournal articlepeer-review

  1. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

    Research output: Contribution to journalJournal articlepeer-review

  2. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

    Research output: Contribution to journalJournal articlepeer-review

  3. Asparaginase Enzyme Activity Levels and Toxicity in Childhood Acute Lymphoblastic Leukemia: a NOPHO ALL2008 study

    Research output: Contribution to journalJournal articlepeer-review

  4. Evans syndrome in adults: an observational multicenter study

    Research output: Contribution to journalJournal articlepeer-review

  1. A nationwide analytical and clinical evaluation of 44 rapid antigen tests for SARS-CoV-2 compared to RT-qPCR

    Research output: Contribution to journalJournal articlepeer-review

  2. Blastic plasmacytoid dendritic cell neoplasm and cerebral toxoplasmosis: a case report

    Research output: Contribution to journalJournal articlepeer-review

  3. Robotic liver resection in Denmark: Report of the first 50 cases at Rigshospitalet Copenhagen

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Recently, reports of severe thromboses, thrombocytopenia, and hemorrhage in persons vaccinated with the chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19, AZD1222, Vaxzevria; Oxford/AstraZeneca) against severe acute respiratory syndrome coronavirus 2 have emerged. We describe an otherwise healthy 30-year-old woman who developed thrombocytopenia, ecchymosis, portal vein thrombosis, and cerebral venous sinus thrombosis the second week after she received the ChAdOx1 nCoV-19 vaccine. Extensive diagnostic workup for thrombosis predispositions showed heterozygosity for the prothrombin mutation, but no evidence of myeloproliferative neoplasia or infectious or autoimmune diseases. Her only temporary risk factor was long-term use of oral contraceptive pills (OCPs). Although both the prothrombin mutation and use of OCPs predispose to portal and cerebral vein thrombosis, the occurrence of multiple thromboses within a short time and the associated pattern of thrombocytopenia and consumption coagulopathy are highly unusual. A maximum 4T heparin-induced thrombocytopenia (HIT) score and a positive immunoassay for anti-platelet factor 4/heparin antibodies identified autoimmune HIT as a potential pathogenic mechanism. Although causality has not been established, our case emphasizes the importance of clinical awareness. Further studies of this potentially new clinical entity have suggested that it should be regarded as a vaccine-induced immune thrombotic thrombocytopenia.

Original languageEnglish
JournalBlood advances
Volume5
Issue number12
Pages (from-to)2569-2574
Number of pages6
ISSN2473-9529
DOIs
Publication statusPublished - 22 Jun 2021

    Research areas

  • Adult, COVID-19, COVID-19 Vaccines, Female, Humans, SARS-CoV-2, Thrombocytopenia/chemically induced, Thrombosis/etiology, Vaccination

ID: 66399024